First evaluation of glucose-6-phosphate dehydrogenase (G6PD) deficiency in vivax malaria endemic regions in the Republic of Korea

• Published in: PloS one 2014-05, Vol.9 (5), p.e97390-e97390
• Main Authors: Goo, Youn-Kyoung, Ji, So-Young, Shin, Hyun-Il, Moon, Jun-Hye, Cho, Shin-Hyung, Lee, Won-Ja, Kim, Jung-Yeon
• Format: Article
• Language: English
• Subjects: Aminoquinolines; Analysis; Anemia; Base Sequence; Blood; Blood tests; Commercialization; Dehydrogenase; Dehydrogenases; Disease control; Enzymes; Ethics; Genetic disorders; Glucose; Glucose 6 phosphate dehydrogenase; Glucose dehydrogenase; Glucosephosphate dehydrogenase; Glucosephosphate Dehydrogenase Deficiency - blood; Glucosephosphate Dehydrogenase Deficiency - epidemiology; Hemolytic anemia; Humans; International marketing; Malaria; Malaria, Vivax - drug therapy; Malaria, Vivax - enzymology; Malaria, Vivax - epidemiology; Malaria, Vivax - prevention & control; Medicine and Health Sciences; Military personnel; Molecular Sequence Data; Mutation; Parasites; Parasitic diseases; Phenotype; Phosphates; Plasmodium falciparum; Plasmodium vivax; Prevalence; Prevention; Primaquine; Primaquine - therapeutic use; Republic of Korea - epidemiology; Sequence Analysis, DNA; Test procedures; Vector-borne diseases
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0097390

Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the most common human enzyme defect and affects more than 400 million people worldwide. This deficiency is believed to protect against malaria because its global distribution is similar. However, this genetic disorder may be associated with potential hemolytic anemia after treatment with anti-malarials, primaquine or other 8-aminoquinolines. Although primaquine is used for malaria prevention, no study has previously investigated the prevalence of G6PD variants and G6PD deficiency in the Republic of Korea (ROK). Two commercialized test kits (Trinity G-6-PDH and CareStart G6PD test) were used for G6PD deficiency screening. The seven common G6PD variants were investigated by DiaPlexC kit in blood samples obtained living in vivax malaria endemic regions in the ROK. Of 1,044 blood samples tested using the CareStart G6PD test, none were positive for G6PD deficiency. However, a slightly elevated level of G6PD activity was observed in 14 of 1,031 samples tested with the Trinity G-6-PDH test. Forty-nine of the 298 samples with non-specific amplification by DiaPlexC kit were confirmed by sequencing to be negative for the G6PD variants. No G6PD deficiency was observed using phenotypic- or genetic-based tests in individuals residing in vivax malaria endemic regions in the ROK. Because massive chemoprophylaxis using primaquine has been performed in the ROK military to kill hypnozoites responsible for relapse and latent stage vivax malaria, further regular monitoring is essential for the safe administration of primaquine.